 This research paper examined the potential of proton pump inhibitors, PPIs, as a novel therapeutic approach for breast cancer and diabetes. The authors used various databases to identify common targets and construct a regulatory network of diseases and drugs. They found that PPIs had a strong affinity for AKT1 and MMP9, two proteins involved in cellular processes such as fatty acid transport, insulin resistance, apoptosis, and cancer-related signalling pathways. These findings suggest that PPIs may be useful in treating breast cancer and diabetes by targeting AKT1 and MMP9. This article was authored by Haifeng Hu, and Bin Wang, Xiaoyun Yang, and others.